UNSPSC 51283209: Tilmicosin

This classification denotes a macrolide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XL4103X2E3. European Medicines Agency schedules Tilmicosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11054MIG. Tilmicosin generally arises in the molecular formula C46H80N2O13. The term TILMICOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) Most nations schedule tilmicosin under HS 29419000 and SITC 54139.

As of Q4 2014, TILMICOSIN remains the US FDA Preferred Term for this commodity. Tilmicosin bears US NLM identifiers UMLS ID C0076681 and NCI Concept Code C84213. SMILES: O(C1C(CCN2CC(CC(C2)C)C)CC(C)C(=O)C=CC(=CC(C(OC(=O)CC(O)C1C)CC)COC1OC(C(O)C(OC)C1OC)C)C)C1OC(C(O)C(N(C)C)C1O)C.

UNSPSC 51283209 Tilmicosin, a Commodity code, nominally covers veterinary pharmaceuticals, but recent state and local procurement activity under this code shows a significant mismatch: the solicitations posted are for naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for fire rescue, and generic multi-source pharmaceuticals—none of which are tilmicosin or veterinary products. The code shows little relevant recent activity aligned with its stated scope. The issuing bodies span county health departments, state health and human services commissions, municipal fire departments, and multistate cooperative purchasing alliances, indicating fragmented procurement across different public-sector customer types. The geographic spread of the recent activity includes Florida, Texas, and Minnesota, representing a scattered pattern rather than concentrated regional demand.

Recent opportunities posted under this code include Seminole County, Florida's IFB 60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2026 (note: the solicitation summary shows an inconsistent date of July 26, 2023, likely a data entry error); the Texas Health and Human Services Commission's RFI HHS0017013 on direct-to-manufacturer prescription programs with a response deadline of April 3, 2026; the City of Tampa's IFB 26P00145 for medical and first aid supplies for the Fire Department Rescue Division with a response deadline of March 13, 2026 and an estimated contract value of $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The mismatch between the code's stated product and the actual procurements suggests the code may be incorrectly tagged in state and local systems or that tilmicosin demand is not currently visible in recent solicitations.